Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Disease management of gastroesophageal reflux disease Clear all
Completed Phase 4 Interventional

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

NCT00242736
View directory record Official record
Conditions
GERD
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Alabaster, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2009 · Synced Oct 9, 2026, 8:52 AM EDT
Recruiting No phase listed Observational

A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

NCT06660342
View directory record Official record
Conditions
Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 3 Interventional

Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

NCT00171418
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Timeline
2003 – 2005
U.S. locations
2
States / cities
Metairie, Louisiana • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Oct 9, 2026, 8:52 AM EDT
Terminated Not applicable Interventional

Rubber Band Ligation and Mucosectomy for Gastroesophageal Reflux Disease (GERD)

NCT01199679
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Heartburn, Regurgitation, Dyspepsia
Interventions
Mucosectomy, Rubber Band Ligation
Procedure
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 9, 2026, 8:52 AM EDT
Enrolling by invitation Not applicable Interventional

Targeting Hypervigilance and Autonomic Arousal: the Psycho-physiologic Model of Gastroesophageal Reflux Disease (GERD)

NCT04960566
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Cognitive Behavioral Therapy, Sham-SOC Lifestyle Coaching
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Not applicable Interventional Results available

LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve Gastrectomy

NCT02429830
View directory record Official record
Conditions
GERD, Gastroesophageal Reflux Disease
Interventions
LINX device
Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

NCT00001337
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma, Gray Zone Lymphoma
Interventions
Etoposide, Rituximab, Prednisone, Cyclophosphamide, Vincristine, Doxorubicin, MRI, CT, Biopsy, PET scan, Laparotomy, Ondansetron, Prochlorperazine, Omeprazole, Docusate Sodium + Sennosides, Lactulose
Drug · Biological · Diagnostic Test + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2024
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 9, 2026, 8:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

To Determine if Sleep Deprivation Results in Increased Esophageal Acid Exposure

NCT01093339
View directory record Official record
Conditions
Gastroesophageal Disease
Interventions
Not listed
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 9, 2026, 8:52 AM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 1 Interventional

Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux

NCT00864396
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Prevacid
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 9, 2026, 8:52 AM EDT
Withdrawn Phase 4 Interventional

Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain

NCT01637571
View directory record Official record
Conditions
Chest Pain, Gastrointestinal Reflux Disease
Interventions
Dexilant, Dexilant Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Not applicable Interventional

Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease

NCT00998244
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Overweight, Acid Reflux Disease
Interventions
Diet - very low carb or low fat
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Not applicable Interventional

Telehealth-Delivered Gut-Directed Hypnotherapy for Managing GI Health

NCT06890663
View directory record Official record
Conditions
Gastrointestinal Disease, Gastrointestinal Disorders, Nervous System
Interventions
Nonspecific Hypnotherapy for Relaxation, Gut-Directed Hypnotherapy (GDH), 3-month Follow-Up
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 9, 2026, 8:52 AM EDT
Terminated Not applicable Interventional Results available

Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study

NCT01327963
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Transoral Incisionless Fundoplication
Device
Lead sponsor
EndoGastric Solutions
Industry
Eligibility
18 Years to 85 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Ocala, Florida • Salem, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 9, 2026, 8:52 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Evaluation of Lymphatic Response to Physiotherapy in Patients With Swelling Associated With Superficial Venous Disease

NCT07165340
View directory record Official record
Conditions
Chronic Venous Disease
Interventions
Indocyanine Green near infrared fluorescence imaging, advanced pneumatic compression, Duplex ultrasound, compression wrap
Combination Product · Device · Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 9, 2026, 8:52 AM EDT
Completed No phase listed Observational

Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Analysis Only

NCT01536457
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
Children's Center for Digestive Health Care
Other
Eligibility
4 Years to 11 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 4 Interventional

Esomeprazole for Treatment of GERD in Pediatric Patients

NCT00228527
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
24
States / cities
Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Maintenance Intermittent Therapy for Symptomatic GERD Patients

NCT00165841
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Rabeprazole 20 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 9, 2026, 8:52 AM EDT
Recruiting Not applicable Interventional

Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms

NCT06613438
View directory record Official record
Conditions
GERD (Gastroesophageal Reflux Disease)
Interventions
eGERD device, eGERD_Sham
Device
Lead sponsor
Gerd Care Medical Ltd
Industry
Eligibility
22 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease

NCT03619811
View directory record Official record
Conditions
Gastroesophageal Reflux, Laryngopharyngeal Reflux
Interventions
Reflux Band® Upper Esophageal Sphincter (UES) Assist Device
Diagnostic Test
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 4 Interventional

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

NCT00251732
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Standard dose (once daily) PPI plus low-dose antidepressant, Double dose PPI plus evening placebo, Rabeprazole , placebo, placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

NCT05195528
View directory record Official record
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
108
States / cities
Athens, Alabama • Cullman, Alabama • Huntsville, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 4 Interventional Results available

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

NCT00693225
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Omeprazole/sodium bicarbonate
Drug
Lead sponsor
Yvonne Romero
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 9, 2026, 8:52 AM EDT
Completed No phase listed Observational

Pharmacogenetic Testing in Children With Persistent Gastroesophageal Reflux Disease

NCT03005080
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 9, 2026, 8:52 AM EDT